142 related articles for article (PubMed ID: 38763866)
1. Dalbavancin as consolidation antibiotic treatment in infective endocarditis, cardiac implantable electronic devices infection and bacteremia: Clinical experience of 7 years.
Salinas-Botrán A; Olmos-Blanco C; Fernández de Velasco-Pérez D; Guzmán-Carreras A; Morales-Rosas A; Gómez-Ramírez D
Enferm Infecc Microbiol Clin (Engl Ed); 2024 May; ():. PubMed ID: 38763866
[TBL] [Abstract][Full Text] [Related]
2. EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci.
Hidalgo-Tenorio C; Sadyrbaeva-Dolgova S; Enríquez-Gómez A; Muñoz P; Plata-Ciezar A; Miró JM; Alarcón A; Martínez-Marcos FJ; Loeches B; Escrihuela-Vidal F; Vinuesa D; Herrero C; Boix-Palop L; Del Mar Arenas M; Vázquez EG; de Las Revillas FA; Pasquau J;
Int J Antimicrob Agents; 2023 Sep; 62(3):106918. PubMed ID: 37442488
[TBL] [Abstract][Full Text] [Related]
3. DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci.
Hidalgo-Tenorio C; Vinuesa D; Plata A; Martin Dávila P; Iftimie S; Sequera S; Loeches B; Lopez-Cortés LE; Fariñas MC; Fernández-Roldan C; Javier-Martinez R; Muñoz P; Arenas-Miras MDM; Martínez-Marcos FJ; Miró JM; Herrero C; Bereciartua E; De Jesus SE; Pasquau J
Ann Clin Microbiol Antimicrob; 2019 Oct; 18(1):30. PubMed ID: 31629409
[TBL] [Abstract][Full Text] [Related]
4. Dalbavancin as consolidation therapy for infective endocarditis in patients with comorbidity. A real world experience.
Brandariz-Núñez D; Luances-Rodríguez A; Feijoo-Vilanova P; Gutiérrez-Urbón JM; Ramudo-Cela L; Martín-Herranz MI; Margusino-Framiñán L
Rev Esp Quimioter; 2024 Aug; 37(4):334-340. PubMed ID: 38881525
[TBL] [Abstract][Full Text] [Related]
5. Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.
Ioannou P; Wolff N; Mathioudaki A; Spanias C; Spernovasilis N; Kofteridis DP
Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508301
[TBL] [Abstract][Full Text] [Related]
6. Dalbavancin as sequential therapy in infective endocarditis: Real-life experience in elder and comorbid patients.
Aparicio-Minguijón E; Boán J; Terrón A; Heredia C; Puente C; Pérez-Jacoiste Asín A; Orellana MÁ; Domínguez L; Caro JM; López-Gude MJ; Aguilar-Blanco EM; Eixerés-Esteve A; López-Medrano F
Enferm Infecc Microbiol Clin (Engl Ed); 2024 Jun; ():. PubMed ID: 38902152
[TBL] [Abstract][Full Text] [Related]
7. Cost evaluation of continuation of therapy with dalbavancin compared to standard-of-care antibiotics alone in hospitalized persons who inject drugs with severe gram-positive infections.
Donnelly D; Pillinger KE; Debnath A; DePasquale W; Munsiff S; Louie T; Jones CMC; Shulder S
Am J Health Syst Pharm; 2024 May; 81(Supplement_2):S40-S48. PubMed ID: 38465838
[TBL] [Abstract][Full Text] [Related]
8. Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial.
Turner NA; Zaharoff S; King H; Evans S; Hamasaki T; Lodise T; Ghazaryan V; Beresnev T; Riccobene T; Patel R; Doernberg SB; Rappo U; Fowler VG; Holland TL;
Trials; 2022 May; 23(1):407. PubMed ID: 35578360
[TBL] [Abstract][Full Text] [Related]
9. Dalbavancin for infective endocarditis: a single centre experience.
Durante-Mangoni E; Boccia F; Ursi MP; Karruli A; Andini R; Galdo M; Zampino R
J Chemother; 2021 Jul; 33(4):256-262. PubMed ID: 33073724
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
Infect Dis Ther; 2022 Feb; 11(1):423-434. PubMed ID: 34905144
[TBL] [Abstract][Full Text] [Related]
11. A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by
Teigell-Muñoz FJ; Mateos-González M; Bernal Hertfelder E; Sánchez de Torre A; García-Ferrón M; de Cáceres Velasco C; Bueno Muiño C
Eur J Case Rep Intern Med; 2023; 10(1):003654. PubMed ID: 36819647
[TBL] [Abstract][Full Text] [Related]
12. Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care.
Ajaka L; Heil E; Schmalzle S
Antibiotics (Basel); 2020 Oct; 9(10):. PubMed ID: 33076275
[TBL] [Abstract][Full Text] [Related]
13. Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series.
Evins C; Lancaster H; Schnee AE
Ann Clin Microbiol Antimicrob; 2022 Apr; 21(1):16. PubMed ID: 35473711
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin Sequential Therapy for Gram-Positive Bloodstream Infection: A Multicenter Observational Study.
Rebold N; Alosaimy S; Pearson JC; Dionne B; Taqi A; Lagnf A; Lucas K; Biagi M; Lombardo N; Eudy J; Anderson DT; Mahoney MV; Kufel WD; D'Antonio JA; Jones BM; Frens JJ; Baumeister T; Geriak M; Sakoulas G; Farmakiotis D; Delaportas D; Larew J; Veve MP; Rybak MJ
Infect Dis Ther; 2024 Mar; 13(3):565-579. PubMed ID: 38427289
[TBL] [Abstract][Full Text] [Related]
15. Recurrence of bacteremia and infective endocarditis according to bacterial species of index endocarditis episode.
Østergaard L; Voldstedlund M; Bruun NE; Bundgaard H; Iversen K; Pries-Heje MM; Hadji-Turdeghal K; Graversen PL; Moser C; Andersen CØ; Søgaard KK; Køber L; Fosbøl EL
Infection; 2023 Dec; 51(6):1739-1747. PubMed ID: 37395924
[TBL] [Abstract][Full Text] [Related]
16. Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections.
Stroffolini G; De Nicolò A; Gaviraghi A; Mula J; Cariti G; Scabini S; Manca A; Cusato J; Corcione S; Bonora S; Di Perri G; De Rosa FG; D'Avolio A
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145630
[TBL] [Abstract][Full Text] [Related]
17. Use of dalbavancin in infective endocarditis: a case series.
Guleri A; More R; Sharma R; Wong M; Abdelrahman A
JAC Antimicrob Resist; 2021 Sep; 3(3):dlab099. PubMed ID: 34396119
[TBL] [Abstract][Full Text] [Related]
18. Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review.
Fazili T; Bansal E; Garner D; Gomez M; Stornelli N
Int J Antimicrob Agents; 2023 Apr; 61(4):106749. PubMed ID: 36758775
[TBL] [Abstract][Full Text] [Related]
19. Comparison of dalbavancin to standard-of-care for outpatient treatment of invasive Gram-positive infections.
Veve MP; Patel N; Smith ZA; Yeager SD; Wright LR; Shorman MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106210. PubMed ID: 33223119
[TBL] [Abstract][Full Text] [Related]
20. Dalbavancin in Bone and Joint Infections: A Systematic Review.
Lovatti S; Tiecco G; Mulé A; Rossi L; Sforza A; Salvi M; Signorini L; Castelli F; Quiros-Roldan E
Pharmaceuticals (Basel); 2023 Jul; 16(7):. PubMed ID: 37513919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]